Neumora Therapeutics to release phase 3 data on Navacaprant for MDD treatment in 2024. Check out NMRA's catalysts that might ...

White matter alterations within the brain are associated with cognitive impairment among individuals with and without major ...

Lysergic acid diethylamide is under clinical development by Mind Medicine MindMed and currently in Phase II for Major Depressive Disorder.

Transcranial magnetic stimulation for alcohol use disorders is under investigation. Research to date suggests TMS could play ...

The following is a summary of “Service coverage for major depressive disorder: estimated rates of minimally adequate ...

A groundbreaking clinical trial has revealed that nerve-stimulating therapy can bring significant improvements to people with ...

If you’ve been diagnosed with clinical depression, also known as major depressive disorder (MDD), rest assured there are many treatment options available. Some people will experience only one ...

TMS has been approved for treating clinical depression in adults since 2008. Recent effectiveness data with adolescents shows ...

MNMD is developing its lead pipeline candidate, MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized ...

PTSD is a serious mental health condition marked by changes in mood, intrusive memories, avoidant behavior, and a heightened ...

If you or a loved one is struggling with anxiety or depression, contact the Substance Abuse and Mental Health Services Administration (SAMHSA) National Helpline at 800-662-4357 for information on ...

For those with seasonal affective disorder (SAD), the changing of the seasons can bring significant shifts in their mood, ...